[Note: It is ProHealth’s policy to reprint the abstracts of research reported in reputable scientific journals. Our commitment is to keep the patient community informed about what is being published on pertinent subjects – unedited. We also believe it is important and valuable for readers to comment and share their thoughts on these reports, because this is what the scientific community is reading.]
Objective: To provide evidence-based recommendations on the treatment of nervous system Lyme disease and post-Lyme syndrome.
Three questions were addressed:
1. Which antimicrobial agents are effective?
2. Are different regimens preferred for different manifestations of nervous system Lyme disease?
3. What duration of therapy is needed?
Methods: The authors analyzed published studies (1983-2003) using a structured review process to classify the evidence related to the questions posed.
Results: The panel reviewed 353 abstracts which yielded 112 potentially relevant articles that were reviewed, from which 37 articles were identified that were included in the analysis.
n There are sufficient data to conclude that, in both adults and children, this nervous system infection responds well to penicillin, ceftriaxone, cefotaxime, and doxycycline (Level B recommendation).
n Although most studies have used parenteral [by injection or infusion] regimens for neuroborreliosis, several European studies support use of oral doxycycline in adults with meningitis, cranial neuritis, and radiculitis (Level B), reserving parenteral regimens for patients with parenchymal Central Nervous System involvement, other severe neurologic symptomatology, or failure to respond to oral regimens.
n The number of children (> or =8 years of age) enrolled in rigorous studies of oral vs. parenteral regimens has been smaller, making conclusions less statistically compelling. However, all available data indicate results are comparable to those observed in adults.
n In contrast, there is no compelling evidence that prolonged treatment with antibiotics has any beneficial effect in post-Lyme syndrome (Level A).
Source: Neurology. 2007 Jul 3;69(1):91-102. PMID: 17522387, by Halperin JJ, Shapiro ED, Logigian E, Belman AL, Dotevall L, Wormser GP, Krupp L, Gronseth G, Bever CT Jr; Quality Standards Subcommittee of the American Academy of Neurology. Department of Neurosciences, Overlook Hospital, NYU School of Medicine, Summit, NJ, USA.